Online shopping for new crown special drug Paxlovid opens, and you can buy it based on nucleic acid or antigen results

Visit the original URL

In the past few days, the circle of friends has become lively again, and the first sentence of everyone’s mouth has become “Are you yang?” Instead of the previous devil-like fear of the new crown, there is a little more teasing ridicule. With the skyrocketing demand, the topic of special drugs for the new crown has become hot again.

On December 13, 36 Krypton discovered that the new crown consultation clinic of the Internet hospital under 1 Yaowang began to pre-sell the new crown oral antiviral drug Paxlovid (Nimatevir/ritonavir tablets), priced at 2980 yuan / box.

v2_32cff08065034f22b12f64c54152b3fb_img_

Photo provided by netizens

The following is the purchase process of Paxlovid Pfizer’s new crown specific drug:

1. Scan the QR code above on WeChat

2. Mobile phone number verification registration

3. Enter the consultation process and reply to the doctor “New Crown”

4. Upload antigen positive photos

5. Pay after the doctor writes a prescription, the price is 2980 yuan per box (one course of treatment for one person)

6. The shelf life is until March 31, 23, and the shipment will be next week

It is reported that in addition to 1yao.com, all major Internet diagnosis and treatment platforms are now actively deploying the sales of oral drugs for the new crown.

Paxlovid is Pfizer’s original drug for the new crown, which is used to treat adults with mild to moderate new coronavirus infection and high risk factors for severe disease, such as advanced age, chronic kidney disease, diabetes, cardiovascular disease, chronic lung disease, etc. Patients need to take medicine within 5 days of onset of symptoms.

According to the FDA’s previous statement, the drug is suitable for people who are not less than 12 years old, weigh no less than 40 kilograms, and have a positive result of direct detection of the new coronavirus. Side effects of the drug may include impaired taste, diarrhea, high blood pressure, and muscle pain. It is not recommended for people with severe kidney or liver impairment. In addition, the FDA also stated that the authorization of Paxlovid does not include the treatment of critically ill patients with new crowns, nor can it replace vaccines for prevention before and after exposure to new crowns.

On December 23, 2021, the U.S. FDA urgently approved Paxlovid, a new crown specific drug developed by Pfizer, which is the first oral antiviral drug authorized by the FDA to treat new crown disease. Since Paxlovid was approved, more than 3.9 million prescriptions have been filled in the United States.

On February 14, 2022, the State Food and Drug Administration of China also approved the use of Paxlovid in China. China Medicines and Health Industry Co., Ltd. is responsible for the commercial operation of Paxlovid in the Chinese mainland market in 2022. In March, the drug was temporarily included in the medical insurance, and the purchase price of the medical insurance in mainland China was 2,300 yuan. It is reported that this is a 5-day course of medication, which is currently the lowest price level in the world for this original research drug.

On March 15, the key points of the revision of the “Diagnosis and Treatment Program for Novel Coronavirus Pneumonia (Trial Ninth Edition)” issued by the National Health and Health Commission showed that Naimatevir/ritonavir tablets (Paxlovid) approved by the State Food and Drug Anti-coronavirus drugs have been written into the diagnosis and treatment plan.

At present, online drug purchases are at their own expense and have not yet been covered by medical insurance. The price per box is 2,980 yuan, which is higher than the medical insurance purchase price of Paxlovid (2,300 yuan) for medical institutions. Previously, the drug was mainly used for hospitalized patients and used inside the hospital. However, because the indications were mild to moderate patients with new coronavirus infection with high risk of developing severe disease, the number of this group of people admitted to the hospital was not large, so the hospital did not use it. There are not many reserves of oral drugs for the new crown.

Before its release of online sales, Paxlovid and its Indian generics Primovir and Paxista were mainly active in the hospital market and overseas shopping. For example, Shenzhen Third People’s Hospital had previously purchased 1,000 doses of Pfizer’s new crown drug, mainly for patients with high-risk factors for new coronary pneumonia. Among the generic drug production countries authorized by Pfizer, India, as the “world pharmacy”, has 19 companies that have been authorized, and the price of each box of Indian generic drugs ranges from 800 to 2,000 yuan. Therefore, Indian generic drugs Primovir and Paxista are also very popular in the market.

v2_fc8dff65d5a146778a1f5e7fc1151278_img_

Image source: Drug Price Reduction Network

Up to now, there have been two new crown oral drugs approved in China. In addition to Paxlovid, the other is Azvudine produced by real organisms. These two types of drugs are prescription drugs and must be used under the guidance of a doctor or clinical pharmacist. In particular, Paxlovid interacts with many drugs and cannot be taken at your own discretion . According to an infection doctor, ritonavir in Paxlovid can affect drugs that are metabolized by the liver. Generally, almost 80% of the drugs on the market are metabolized by the liver. Taking Paxlovid may interact with other drugs, resulting in an increase or decrease in the efficacy of the drug. “This may be fatal.”

Just on November 19, Azvudine also caused a storm of online sales . Some pharmacies on online platforms such as Meituan and Ele.me began online pre-sales. The price was around 350 yuan, but it was quickly stopped. , urgently removed from the shelves. Some experts responded, “Azvudine is a prescription drug, and it is approved by emergency authorization. It should follow the treatment guidelines. It is not suitable for self-administration, and it is not suitable for online sales.”

Now the policy has been opened. On December 11, the medical treatment team of the State Council’s joint prevention and control mechanism for the new crown epidemic issued the “Notice on Doing a Good Job in Internet Medical Services for New Coronary Pneumonia” , allowing Internet hospitals to provide the first diagnosis for people infected with the new crown. This seems to be contrary to the previously released “Internet Diagnosis and Treatment Rules (Trial)”, and has also aroused public doubts about the arbitrariness of the decree.

v2_52b69f6b13174380a05ff353cf5e28a0_img_

Image source: Official website of the National Health Commission

media reports

Sina Sina 36Kr Sina Sina Titanium Media Sina Titanium Media Sina NetEase Technology Sina Sina 36Kr Surging News
Event Tracking

This article is transferred from: https://readhub.cn/topic/8lIlcki1Azc
This site is only for collection, and the copyright belongs to the original author.